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Abstract
Background: To investigate the effects of short-term continuous subcutaneous insulin infusion (CSII) on plasma fibroblast
growth factor-21 (FGF-21) levels in patients with newly diagnosed type 2 diabetes mellitus (nT2DM).
Method: Sixty-eight patients with nT2DM (nT2DM group), and 52 gender-, age- and body mass index (BMI) -matched
normal glucose tolerance (NGT group) controls participated in the study. 30 nT2DM patients with FBG$14.0 mmol/L were
treated with CSII for 2 weeks, and were underwent a euglycemic–hyperinsulinemic clamp pre- and post-treatment. Plasma
FGF-21 concentrations were measured with a commercial ELISA kit. The relationship between plasma FGF-21 levels and
metabolic parameters was also analyzed.
Results: Fasting plasma FGF-21 levels were higher in the nT2DM group than in NGT groups (1.6060.08 vs. 1.1360.26 mg/L,
P,0.01). In nT2DM patients, fasting plasma FGF-21 concentrations were significantly decreased after CSII treatment for 2
weeks (1.6060.08 vs.1.3060.05 mg/L, P,0.05), accompanied by a significant increase in the whole body glucose uptake (M
value) and blood glucose control. The changes in plasma FGF-21 levels (DFGF-21) were positively associated with the
amelioration of insulin resistance shown by the changes in M value.
Conclusion: Plasma FGF-21 level is associated with whole body insulin sensitivity and significantly reduced following short-
term CSII treatment.
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Introduction
Fibroblast growth factors (FGFs) represent a group of peptides
that regulate diverse biological functions, including cell differen-
tiation, cell growth, and angiogenesis [1,2]. Recently, a subfamily
of FGFs that interact with nuclear receptors has been identified
that plays an important role in liver, bone, and adipose tissue
metabolism [3–4]. In murine models, Fibroblast growth factor 21
(FGF-21) was reported to be expressed predominantly in liver [5],
but its expression has also been reported in adipose tissue and
pancreatic b-cells [6]. It is a potent metabolic regulator shown to
improve insulin resistance as well as to reduce overall body weight
and adipose mass [7–13]. Pharmacologically, FGF-21 induced
glucose uptake through the induction of glucose transporter-1
(GLUT1) in adipocytes, and in vivo treatment with FGF-21 resulted
in amelioration of glucose and lipid metabolism in both murine
and nonhuman primate models of diabetes or obesity [11,
14–15]. Furthermore, mice overexpressing FGF-21 was resistant
to diet-induced obesity and exhibited improved glucose homeo-
stasis [11]. FGF-21 knockout (FGF-21KO) mice developed mild
obesity and impaired glucose homeostasis, as these mice aged [16].
We had previously demonstrated that plasma FGF-21 levels were
elevated in patients with type 2 diabetes mellitus (T2DM) [17],
and were decreased in response to treatment with rosiglitazone
[18]. More recently, Zhang et al. [19] found that FGF-21
concentrations were elevated in obese nondiabetic individuals
compared with lean healthy control subjects and that the
circulating levels correlated positively with adiposity and fasting
insulin and negatively with HDL cholesterol. Conversely, in
patients with anorexia nervosa, plasma FGF-21 concentrations
were decreased and increased following weight gain [20].
Since the role of FGF-21 in human physiology remains to be
elucidated, it is important to characterize the effect of common
anti-diabetic treatment on the plasma levels of FGF-21. Transient
insulin treatment optimized by continuous subcutaneous insulin
infusion (CSII) is effective in rapidly reducing hyperglycemia and
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T2DM [21]. CSII, which mimics physiological insulin secretion,
becomes feasible, and results in fewer side effects by flexible and
episodic insulin adjustment. Early intensive insulin therapy in
patients with newly diagnosed T2DM (nT2DM) recovers b-cell
function to a certain degree, along with a concurrent improvement
in insulin sensitivity [22,23]. Thus, the aim of this study was to
examine plasma FGF-21 levels in nT2DM patients and to evaluate
the effects of CSII treatment for two weeks on plasma FGF-21
level in these patients.
Results
The clinical characteristics and fasting plasma FGF-21
levels
The clinical characteristics of the two groups did not show
significant difference in gender distribution, age, BMI, Fat %,
blood pressure and HDL-C (Table 1). WHR, TC, TG, LDL-C,
FBG, 2 h OGTT and HbA1c in nT2DM group were higher than
NGT group (P,0.05 and P,0.01). Compared with the NGT
group, the patients with nT2DM had higher HOMA-IR (P,0.01),
but lower fasting plasma insulin (FINS) and HOMA-IS (P,0.01).
There was significant difference in fasting plasma FGF-21 levels
between the nT2DM and NGT groups (1.6060.08 vs.1.136
0.26 mg/L, P,0.01). However, no sexual dimorphism became
apparent in plasma FGF-21 levels (P=NS).
Relationship between fasting plasma FGF-21 levels and
metabolic parameters
Bivariate correlation analyses were performed to assess relation-
ships between plasma FGF-21 concentrations and body composi-
tion or metabolic parameters. Fasting plasma FGF-21 was found to
correlate positively and significantly with HbA1c (r=0.59,
P,0.01). systolic blood pressure (SBP, r=0.17, P,0.05), diastolic
blood pressure (DBP, r=0.18, P,0.05), FBG (r=0.52, P,0.01),
2 h OGGT (r=0.57, P,0.01), HDL-C (r=0.18, P,0.05) and FFA
(r=0.18, P,0.05), but negatively with FINS (r=20.28, P,0.01),
PINS (r=20.24, P,0.01) and HOMA-IS (r=20.54, P,0.01).
Multiple regression analysis showed that DBP, WHR, 2 h
plasma insulin after glucose overload (PINS), 2 h OGTT and
FFA were independent related factors influencing plasma FGF-21
levels (YFGF-21=3.186+0.058X2 h OGTT20.007XPINS+0.491XFFA
+3.206XWHR+0.021XDBP).
The effects of CSII on clinical characteristics and FGF-21
levels in nT2DM patients
30 nT2DM patients treated with CSII achieved excellent
glycemic control within 3–5 days and maintained euglycemia in
the following 2 weeks. After 2 week of CSII therapy, blood glucose
control was remarkably improved. As shown in Table 1, there was
a significant decrease in FBG, 2 h OGTT and HbA1c (all
P,0.01), and an increase in insulin levels, including FINS and
PINS (P,0.05 and P,0.01). Treatment with CSII decreased
Table 1. Clinical characteristics and FGF-21 levels of study subjects.
Group T2DM Post-treatment NGT
BMI(kg/m2) 24.062.3 24.562.3 23.964.2
WHR 0.8960.04* 0.8960.05 0.8560.08
Body fat(%) 27.762.6 27.762.6 30.067.9
SBP(mmHg) 130611 123613 125618
DBP(mmHg) 81687 5 658 0 69
TG(mmol/L) 3.7461.98** 3.2161.51
m 1.7961.24
TC(mmol/L) 5.0760.83* 3.3762.17
mm 4.7162.02
HDL-C (mmol/L) 1.3260.93 1.1960.25 1.3160.36
LDL-C (mmol/L) 3.3961.14** 2.5660.71
mm 2.6960.68
FFA (umol/L) 0.95 (0.54–2.55) 0.81 (0.12–2.86) 0.8560.53
HbA1c(%) 10.761.5** 8.9861.16
mm 5.960.3
FBG(mmol/L) 14.561.6** 6.060.9
mm 5.760.3
2hOGTT(mmol/L) 21.664.6** 7.160.7
mm 6.060.9
FINS(mU/L) 6.7 (2.59–10.37)* 8.81 (4.61–26.56)
m 12.37(5.29–60.20)
PINS(mU/L) 20.65 (4.1–56.26) 45.45(12.44–92.78)
m 29.09(7.09–87.40)
HOMA-IR 4.28 (1.7–6.47)** 2.3 (1.09–7.2)
mm 2.98(0.71–15.41)
HOMA-IS 13.20 (4.09–21.8)** 78.21(46.75–204.31)
mm 140.92(32.5–539.2)
FGF-21(mg/L) 1.6060.08** 1.3060.05
m 1.1360.26
M (mg/kg/min) 2.9960.42 5.1060.51
mm -------------
M/I[mg/kg/Min/(mU/l)] 0.1960.04 0.4360.09
mm --------------
Data are means 6 S.D. or median. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; WHR, waist-to-hip ratio; fat%, visceral fat %; FBG,
fasting blood glucose; 2 h OGTT, 2 h post-glucose load blood glucose; FINS, fasting plasma insulin; PINS, 2 h plasma insulin after glucose overload; HOMA-IR, HOMA-
insulin resistance index; HOMA- IS, HOMA - b-cell insulin secretion index; FFA, free fatty acids; TG, total triglyeride; TC, total cholesterol; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c,glycosylated hemoglobin.
*P,0.05,
**P,0.01 compared with NGT group;
mP,0.05,
mmP,0.01 compared with pre-treatment.
doi:10.1371/journal.pone.0026359.t001
Effects of Short-Term CSII on FGF-21 in New T2DM
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26359plasma TG, TC and LDL-C levels (P,0.05 or P,0.01). Also,
elevated fasting plasma FGF-21 levels were decreased (1.6060.08
vs. 1.3060.05, P,0.05, Figure 1) concomitant with ameliorations
in insulin resistance and b-cell dysfunction, which were shown by a
significant decrease in HOMA-IR values and a significant increase
in HOMA-IS values (both P,0.01, Table 1).
To directly examine the quantitative effect of CSII treatment on
insulin sensitivity, we performed EHC on the same group of
patients pre- and post-treatment. During the last hour of the
clamps, glucose concentrations were 5.960.3 and 6.060.4 mmol/
L, respectively, pre and post CSII treatment (differences not
statistically significant). Fasting insulin concentrations were 6.7
(2.59–10.37) mU/L pre CSII treatment and increased to 8.81
(4.61–26.56) mU/L (P,0.05). During the last hour of the clamps,
serum insulin concentrations were 28.464.9 and 30.265.9 mU/L
pre- and post- CSII treatment, respectively (differences not
significant). CSII treatment resulted in a significant increase in
glucose disposal rate shown as M values (5.1060.51 vs.
2.9960.42 mg/kg/min, P,0.01) and insulin sensitivity index
shown as M/I (0.4360.09 vs. 0.1960.04 mg/kg/min mU/l,
P,0.01, Table 1). We also assessed the associations between the
changes of plasma FGF-21 (DFGF-21) and several parameters pre-
and post- CSII treatment. Interestingly, DFGF-21 was positively
associated with DDBP (r=0.478, P,0.01), but negatively DHDL
(r=20.395, P,0.01). More important, to investigate the associ-
ation of plasma FGF-21 and insulin resistance, multiple regression
analyses in the subgroup of patients with EHC revealed a strong
association DFGF-21 with M values (R2=0.565, B=20.266,
P,0.01).
Discussion
FGF-21 was discovered during a high-throughput assay for
secreted proteins that increased glucose uptake in 3T3L-1
adipocytes [11]. Subsequent studies [4,11,15] showed that
administration of recombinant FGF-21 in rodent models of
diabetes and in diabetic rhesus monkeys improved blood glucose
and the lipid profile. In addition, it had been demonstrated that
plasma FGF-21 levels were elevated in insulin-resistant states
(obesity, IGT/IFG, T2DM) and were inversely correlated with
both peripheral and hepatic insulin sensitivity [24]. However,
fewer studies compared plasma FGF-21 levels before and after
anti-diabetic agents. In the current study, we found that plasma
FGF-21 levels were elevated in patients with new-onset T2DM
compared with the gender-, BMI- and age-matched NGT
subjects. Furthermore, we found that fasting plasma FGF-21 was
positively and significantly correlated with SBP, DBP, FBG, 2 h
OGTT, HbA1c, HDL-C and FFA, but negatively with FINS,
PINS and HOMA-IS. Therefore, the most likely explanation for
these findings is that elevated FGF-21 levels in nT2DM patients
might represent a compensatory mechanism in response to
decreased insulin sensitivity or impairment of glucose metabolism.
Another explanation could be that elevated FGF-21 levels in these
patients may be a compensatory response to decreased fasting
plasma insulin levels due to a defect in beta cell function. These
results were consistent with our and other reports [17,19] in
humans that demonstrated elevated plasma FGF-21 concentration
in obesity, IGT, and T2DM. These data further suggested that
T2DM or obesity might also have an FGF21-resistant state [25].
We had previously demonstrated a decrease in fasting plasma
FGF-21 after treatment with rosiglitazone in T2DM [18]. We
considered that this decrease could be caused by the improved
insulin resistance via rosiglitazone treatment. In the current study,
blood glucose, both postprandial and fasting glucose levels, were
nearly normalized within 7 days and the euglycemia was
maintained for 2 weeks by CSII therapy in patients with severe
nT2DM. Meanwhile, TG, TC, LDL-C and HbA1c were also
significantly lower after CSII therapy. These findings indicated the
amelioration of glucose-lipid metabolism. In addition, increasing
insulin levels and HOMA-IS indicated an amelioration of
glucotoxicity and b-cell dysfunction after treatment with CSII in
these patients. Furthermore, EHC showed that M and M/I values
Figure 1. Plasma FGF-21 levels pre- and post-treatment with CSII in 30 nT2DM patients with FBG$14.0 mmol/L. * P,0.05 vs. pre-
treatment.
doi:10.1371/journal.pone.0026359.g001
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amelioration of insulin resistance. Interestingly, along with the
rapid improvement in glucose-lipid metabolism and insulin
resistance, and elevated plasma insulin, we observed a dramatic
decrease in fasting plasma FGF-21 concentrations in these
patients. More importantly, the reduction of plasma FGF-21
levels was found to associate with the amelioration of insulin
resistance shown by a significant relationship between DFGF-21
and M values in T2DM patients with EHC. Hence, the regulation
of circulating FGF-21 might be influenced by metabolic control,
insulin resistance and b cell function. Decreased circulating FGF-
21 after CSII treatment might also mediate the improvement of
insulin resistance in the nT2DM patients. However, we cannot
also rule out the possibility that infusion of insulin is reducing
FGF-21 levels. In addition, CSII treatment may improve FGF-21
action and consequently alleviate FGF-21 resistance, and reduces
plasma FGF-21 levels, but this needs further investigation.
In conclusion, our study found that circulating FGF-21 levels
were significantly increased and significantly associated with
HbA1c, FBG, 2 h OGTT, HDL-C, FFA, insulin and HOMA-
IS in nT2DM. More importantly, we presented, for the first time
to our knowledge, a novel data that CSII treatment significantly
decreased plasma FGF-21 levels in these patients. The reduction
of plasma FGF-21 levels was found to associate with the
amelioration of insulin resistance shown by a significant relation-
ship between DFGF-21 and M values in EHC. Taking these
findings into consideration, our results supported the hypothesis
that FGF-21 may be an insulin sensitizing cytokine in humans.
Materials and Methods
Subjects
120 volunteers were involved in this study and categorized into
two groups. Sixty-eight subjects with nT2DM and 52 control
subjects participated in the study. The diagnostic criteria of T2DM
was based on a 75 g oral glucose tolerance test (OGTT)
recommended by World Health Organization criteria [26]. These
patients had not taken any diabetic medications/diet prior to the
present study. Patients with a history of unstable proliferative
retinopathy, evidence of liver disease, renal dysfunction, severe
cardiac problems, uncontrolled hypertension, or type 1 diabetes
were excluded. 52 healthy volunteers, age- and BMI matched with
nT2DM groups, were chosen as the normal controls (NGT group).
These subjects without clinical evidence of major disease were
recruited from an unselected population that underwent routine
medical check-ups and did not receive any therapy. Their non-
diabetic status was confirmed with a normal OGTT. This study
was carried out in accordance with the recommendations of the
Declaration of Helsinki. The study was approved by the Human
Research Ethics Committee of Chongqing Medical University. A
written informed consent was obtained from all participants in this
study.
Study design
Anthropometric measurement was performed in the morning,
before breakfast, with the subject wearing light clothing, without
shoes. Body weight and height were measured by the same
observer using a scale and a wall-mounted stadiometer to 0.5 kg
and 0.5 cm, respectively. Waist and hip circumferences were
measured, and the waist to hip ratio (WHR), which provided
valuable information about the distribution of body fat, was
calculated as the ratio of waist and hip circumferences. Standard
procedures were followed [26], and the average of the two
measurements was taken. After 1.75 g/kg body weight (maximum
75 g) of glucose was administered as 20% glucose solution, venous
blood was sampled at baseline and 120 min. Plasma glucose level
and HbA1c were immediately measured by the glucose-oxidase
technique or anion exchange HPLC respectively, to avoid
anaerobic glucose consumption. Plasma was then stored at
280uC for determination of plasma free fatty acid (FFA), insulin,
FGF-21 and blood fat levels.
Thirty patients only with FBG$14.0 mmol/L were admitted
to the hospital, and then treated with intensive insulin therapy by
CSII with MiniMed 712E insulin pumps (Medtronic MiniMed,
Northridge, CA, USA). The initial daily insulin (Insulin aspart,
Novo Nordisk, Denmark) dose was calculated as follows: total
insulin dose daily=(0.4–0.6) unit 6body weight (kg). The basal
rate (Units/hour) was calculated as 50% of the total insulin dose,
and other 50% was administered as preprandial boluses before
each of three meals. The basal and boluses of insulin infusion
were adjusted according to preprandial and postprandial
capillary blood glucose. Excellent blood glucose control was
defined as FBG,6.1 mmol/l and postprandial blood glucose
(2hPBG),7.8 mmol/l, and was achieved within 3–5 days. After 2
weeks of CSII, insulin treatment was stopped. Other 38 patients
with FBG#14.0 mmol/L were treated with anti-diabetic agents
or only diet and exercise.
Euglycemic–hyperinsulinemic clamp (EHC) was performed in
16 of the 30 T2DM subjects before CSII, and was repeated at least
24 h after insulin cessation. Briefly, after an overnight fast, an
intravenous catheter was placed in the antecubital vein to infuse
insulin and glucose. Another catheter was placed retrograde in the
dorsal vein of the contralateral hand for blood withdrawal. This
arm was wrapped with a heating blanket (,70uC) to arterialize
venous blood. Regular human insulin (Humulin; Eli Lilly,
Indianapolis, IN) was infused at a rate of 2 mU ? kg
21? min
21
to raise insulin concentrations to 200 mU/ml and a variable
infusion of 20% glucose was administered to maintain plasma
glucose at ,6 mmol/L for 2 h. During the procedure, plasma
glucose was measured every 5 min to guide the glucose infusion.
The rate of glucose disposal was defined as the glucose infusion
rate (GIR) during the stable period of the clamp and was related to
body weight (M value, mg/kg per min) [27]. The insulin sensitivity
index (M/I) was calculated as the whole body glucose uptake (M
value) divided by insulin concentration (I value). No anti-diabetic
agents, oral contraceptives or anti- hyperlipidemic agents were
used during the study. No subject dropped out of the study. Blood
samples were taken before CSII treatment and after at least 24 h
insulin cessation for the measurements of metabolic parameters
and plasma FGF-21 levels.
Plasma biochemical parameters and FGF-21
Plasma FGF-21 levels were measured with a commercial ELISA
kit (Adipobiotech, Inc., Beijing, China). The linear range of the
assay was 0.5–8.5 mg/L, and the standard range was 0.13–20 mg/
L. The inter- and intra-assay coefficients of variation were 10 and
5% respectively. Plasma insulin concentration was measured by
radioimmunoassay (Diagnostic Products, Los Angeles, CA). FFA
were measured with a commercial assay kit (Randox Laboratories
Ltd, Antrim, UK). Triglyceride (TG), cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and lowdensity lipopro-
tein cholesterol (LDL-C) concentrations were determined enzy-
matically. Percent body fat (Fat %) was determined by bioelectrical
impedance analysis (Tanita, Inc., Tokyo, Japan). The homeostasis
model assessment of IR (HOMA-IR) and the HOMA of b-cell
insulin secretion (HOMA-IS) were calculated from fasting insulin
(FINS) and glucose levels using following equations:
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Fasting insulin (mU=L)|FBG (mmol=L)
22:5
HOMA-IS~
20|FINS (mU=L)
FBG (mmol=L){3:5
[28].
Statistical analysis
Statistical analyses were performed using the SPSS 15.0
software (SPSS, Chicago, IL, USA). Since the distributions of
plasma insulin, HOMA-IR and HOMR-IS values were skewed,
logarithmically transformed values were used for statistical
analysis. Baseline characteristics of case and control subjects were
compared by t-test. The paired t-test was used to compare
differences in biochemical characteristics and FGF-21 levels
between pre- and post-treatment with CSII in nT2DM group.
Bivariate correlation and multiple regression analyses were used to
examine the association between fasting plasma FGF-21 levels and
the values of other biomarkers. There was no existence of the
multicollinearity between all the variables included in the multiple
regression analyses. All of the statistical analyses were two-sided,
and all data were presented as means 6S.D. with a P value,0.05
considered statistically significant.
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